A Research Study of How a New Medicine NNC0365-3769 (Mim8) Works in the Body of Healthy People

    Not Recruiting
  • participants needed
  • sponsor
    Novo Nordisk A/S
Updated on 5 July 2022
Accepts healthy volunteers


NN0365-3769 (Mim8) is a study medicine with the potential to prevent and reduce bleeding in people with haemophilia A (an inherited disorder in which blood does not coagulate properly).

This study will investigate if different doses of Mim8 are safe, and also check how Mim8 behaves in the body.

Twelve different doses will be tested. Participants will only get one of the doses. Which dose participants get is decided by chance. Participants will get a single injection under the skin of the belly by means of a syringe and a needle.

The study will last for about 17 - 21 weeks.

Condition Healthy Volunteers - Haemophilia A
Treatment Mim8 B, 10 mg/mL, Mim8 B, 100 mg/mL, Mim8 B, placebo
Clinical Study IdentifierNCT05127473
SponsorNovo Nordisk A/S
Last Modified on5 July 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note